Inventiva (NASDAQ:IVA) Stock Price Up 0.8% – Here’s Why

Inventiva S.A. (NASDAQ:IVA)’s stock price was up 0.8% during mid-day trading on Tuesday . The company traded as high as $3.67 and last traded at $3.65. Approximately 8,903 shares were traded during trading, a decline of 86% from the average daily volume of 64,692 shares. The stock had previously closed at $3.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on IVA shares. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Inventiva in a research note on Friday, March 28th. TD Cowen assumed coverage on Inventiva in a research report on Friday, February 21st. They set a “buy” rating and a $10.00 price objective for the company. Finally, Guggenheim reduced their price objective on Inventiva from $12.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, April 4th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Inventiva Stock Up 0.8%

The company has a fifty day moving average of $3.41 and a two-hundred day moving average of $2.86.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,715 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.